First humans dosed in early trial for future fibrosis and cancer drug
NCT ID NCT05740475
Summary
This was the first time a new drug called 9MW3811 was given to people. The main goal was to check if it was safe and how the body handled it in 32 healthy adult volunteers. This early safety study is a necessary first step before testing if the drug can help treat conditions like lung scarring (pulmonary fibrosis) and tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.